We’re thrilled by the overwhelming response to Wesley Research Institute’s Coeliac Disease Webinar held on Septmeber 23rd. The strong interest in our coeliac disease webinars reflects a growing eagerness to better understand the latest research and treatment developments for coeliac disease.
Over 140 participants tuned in live to the session, which delivered valuable insights into the findings of the Gluten Threshold Study, exploring how researchers identified the levels at which gluten can trigger an immune response, what these results mean for people living with coeliac disease, and how the findings could influence gluten-free standards and guidelines both in Australia and around the world.
Watch Webinar
Watch the Coeliac Disease Webinar recording here – https://youtu.be/Ugto0XhnHIQ
Key insights from listening to Dr James Daveson:
Why was this study important?
For decades, gluten-free food regulations around the world have been based on limited evidence about how much gluten can be safely consumed by people with coeliac disease.
Many patients report becoming “glutened” after eating out or consuming foods they believed were safe. However, researchers have had limited tools to accurately measure what happens in the body following very small amounts of gluten exposure.
The Gluten Threshold Study was designed to answer an important question:
At what level does gluten begin to trigger an immune response in people with treated coeliac disease?
How was the study conducted?
Researchers recruited adults with well-controlled coeliac disease who were following a strict gluten-free diet.
Rather than relying solely on bowel biopsies, the study used a highly sensitive blood biomarker called Interleukin-2 (IL-2), which is released when gluten-specific immune cells become activated.
Participants received carefully controlled gluten challenges ranging from:
1,000 mg
610 mg
90 mg
13 mg
8 mg
5 mg
3 mg
2 mg
1 mg
Placebo
Researchers then measured immune activity through blood tests and tracked participant symptoms following each challenge.
What did the researchers find?
Even tiny amounts of gluten can activate the immune system
The study demonstrated that measurable immune responses occurred at much lower doses than previously investigated.
The lowest observed effect level was 3 milligrams of gluten, meaning that this was the smallest dose shown to trigger a measurable immune response in some participants.
Importantly, the immune response became progressively smaller as the gluten dose decreased, but did not disappear entirely until extremely low levels were reached.
One of the most interesting parts of the study was understanding just how small these gluten doses actually are.
To put the amounts into context, a standard slice of bread contains approximately 3,000 milligrams of gluten. During the study, researchers tested doses ranging from 1,000 milligrams all the way down to just 1 milligram of gluten.
The study found that 3 milligrams of gluten was the lowest dose to trigger a measurable immune response in some participants. That means a response was detected at just 0.1% of the gluten found in a single slice of bread.
Symptoms don’t always tell the full story
One of the most surprising findings was that participants often could not reliably distinguish between low-dose gluten exposure and placebo.
While larger doses of gluten produced stronger immune responses, people exposed to low amounts of gluten frequently reported similar symptoms regardless of whether they received gluten or placebo.
This suggests that:
- Some people may experience immune activation without noticeable symptoms.
- Symptoms alone may not always be a reliable indicator of accidental gluten exposure.
- Ongoing bowel damage may occur even when someone does not feel unwell.
What does this mean for food labelling?
The findings provide important context for global gluten-free regulations.
Internationally, many countries allow foods labelled “gluten-free” to contain up to 20 parts per million (ppm) of gluten.
The study explored what this means in practical terms. For example:
A standard serve of pasta manufactured at 20 ppm may expose someone to approximately 3 mg of gluten. In Australia and New Zealand, gluten-free standards are significantly stricter, with products required to contain no detectable gluten.
While the research does not automatically change existing regulations, it provides new evidence that may inform future discussions about gluten-free labelling and consumer safety.
Implications for future treatments
The study also has implications beyond food labelling.
Because IL-2 proved to be a highly sensitive marker of immune activation, it could become an important tool for:
- Evaluating new therapies for coeliac disease
- Measuring treatment effectiveness in clinical trials
- Better understanding individual differences in gluten sensitivity
Researchers believe this approach may help accelerate the development of future treatments aimed at protecting people with coeliac disease from accidental gluten exposure.
Key takeaways
- The Gluten Threshold Study was the first to examine immune responses to micro-amounts of gluten.
- A measurable immune response was observed at doses as low as 3 mg of gluten.
- People often could not identify low-dose gluten exposure based on symptoms alone.
- The findings provide valuable new evidence for discussions around food labelling standards and future coeliac disease treatments.
- IL-2 may offer researchers an important new way to measure immune responses and evaluate emerging therapies.
Learn more about the Gluten Threshold Study by reading the article published in Gastroenterology.
Stay Engaged
Wesley Research Institute is committed to keeping the coeliac community informed and engaged.
“We encourage anyone interested to follow our research, participate in trials and stay up to date with new developments through our Coeliac Research Network,” Dr Daveson said.
Learn more about our Coeliac Disease and Immune Health Research Program, or if you haven’t already become an active member of our Coeliac Research Network.
Stay tuned for future webinars and research updates as the journey towards better treatments for coeliac disease continues. Don’t miss out, sign up for the next webinar.